Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Naomi Cornish et al, adding:
”Associations of Tumor Somatic Mutations with Cancer-Associated Venous Thromboembolism
Analysis of 12,507 cancer patients reveals that somatic mutations in CDKN2A, KRAS, PCDH15, and TP53 significantly increase VTE risk, while high tumor mutational burden is protective, offering novel insights into cancer-associated thrombosis pathophysiology and future risk prediction tools.”
Title: Associations of tumor somatic mutations with cancer-associated venous thromboembolism
Authors: Naomi Cornish, Rebecca Ward, Matthew T. Warkentin, Chrissie Thirlwell, Andrew D. Mumford, Sarah K. Westbury, Philip C. Haycock
Read the Full Article on JTH

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation
-
Aug 21, 2026, 09:07Sujal Lohana: Building a Better Blood Donor–Seeker App
-
Aug 21, 2026, 08:55Robert Sidonio: Connecting Experts in Bleeding and Clotting Disorders
-
Aug 21, 2026, 08:44Gladys Delancey: Understanding Blood Clots and Their Warning Signs
-
Aug 21, 2026, 08:32Brian Freeman: Supporting Innovation in Rare Blood Disorders
-
Aug 21, 2026, 07:46Mallikarjuna Rao Dubisetty: Thalassemia Awareness – What Every Parent Should Know
-
Aug 20, 2026, 19:46Haseeb Raza: A Practical Guide to Managing Bleeding on Anticoagulant Therapy
-
Aug 20, 2026, 19:44Harshi Peiris: 2026 Cholesterol Guidelines Bring Earlier and More Precise Risk Assessment